Wave Life Sciences reported strong advancements in its clinical pipeline during Q3 2025, particularly with WVE-007 demonstrating significant potential for weight loss and improved metabolic health through its unique mechanism of action.

• WVE-007 showed impressive dose-dependent reductions in activin E of up to 85%, indicating strong efficacy in its first clinical trial cohorts.
• Enrollment in the Enlight trial is progressing well, with over 70 participants and a plan to report on more than 100 by 2026.
• Positive feedback from recent presentations at Obesity Week highlights industry recognition for WVE-007's potential to offer a convenient treatment alternative to current therapies.
• WVE-006 is advancing as a potential first-in-class treatment for AAT deficiency, differentiating itself through its simple subcutaneous dosing regimen.
• The company anticipates delivering multiple key updates in the coming months, reflecting on early impacts on weight loss and metabolic health markers.